Biotech business models have shifted from a high-risk, asset-centric approach to a platform-based model. Companies now focus on securing multiple early-stage partnerships, which is more capital-efficient and preserves optionality in a rapidly changing therapeutic landscape.
Modern biotech startups succeed by outsourcing non-core functions, such as medicinal chemistry, that have become commoditized. This lean approach allows them to focus capital and talent on their unique, best-in-class technology, enabling them to do more with less funding.
Platform-based biotech companies need a new generalist role that combines deep scientific knowledge with product creativity and business development skills. These individuals create multiple 'front doors' for partners but are hard to find in a field historically dominated by specialists.
By deliberately not over-raising, biotech startups preserve M&A optionality. A seemingly modest exit, like Surf Bio's $400M acquisition, can be a massive win for founders and early investors if the company remained lean, avoiding the need for a billion-dollar outcome.